chloroquine has been researched along with ritonavir in 90 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (7.78) | 29.6817 |
| 2010's | 12 (13.33) | 24.3611 |
| 2020's | 71 (78.89) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Andrews, KT; Gardiner, DL; McCarthy, J; Melville, L; Skinner-Adams, TS | 1 |
| Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J | 1 |
| Andrews, KT; Anstey, NM; Boonma, P; Gardiner, DL; Lek-Uthai, U; Machunter, B; McCarthy, JS; Nosten, F; Piera, KA; Price, RN; Ruengweerayut, R; Russell, B; Skinner-Adams, TS; Suwanarusk, R | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Andrews, KT; Butterworth, AS; Eickel, N; Gardiner, DL; MacDonald, T; McCarthy, JS; Peatey, CL; Skinner-Adams, TS; Trenholme, KR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Campbell, MA; Chen, X; Ding, K; Eickhoff, CS; Goldberg, DE; Griggs, DW; He, Z; Jacobsen, EJ; Lang, X; Liu, X; Lu, X; Lu, Y; Meyers, MJ; Oliva, J; Prinsen, MJ; Qin, L; Ruminski, PG; Sverdrup, FM; Tortorella, MD; Tu, Z; Wood, DC; Xu, J; Xu, W; Zeng, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hoppe, HC; Isaacs, M; Kaye, PT; Krause, RWM; Manyeruke, MH; Seldon, R; Tshiwawa, T; Warner, DF | 1 |
| Andrews, KT; Gardiner, DL; Kelly, M; McCarthy, JS; Ray, J; Redmond, AM; Skinner-Adams, T | 1 |
| Chen, L; Chen, X; He, Z; Qin, L; You, J | 1 |
| Butterworth, AS; Gardiner, DL; Kirk, K; Martin, RE; McCarthy, JS; Skinner-Adams, TS | 1 |
| Maxmen, A | 1 |
| Duan, Y; Zhou, C; Zhu, HL | 1 |
| Cohen, J; Kupferschmidt, K | 1 |
| Hong, W | 1 |
| Chen, B; Chen, H; Hong, Z; Huang, M; Jiang, S; Kong, L; Li, M; Liang, J; Lu, J; Ma, R; Pang, P; Pei, D; Qin, D; Shan, H; Shu, J; Tang, T; Xia, J; You, Y | 1 |
| Barlow, A; Barlow, B; Claassen, CW; Heavner, JJ; Heavner, MS; Landolf, KM; Yeung, SYA | 1 |
| Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
| Şimşek Yavuz, S; Ünal, S | 1 |
| Aryal, D; Beane, A; Dondorp, AM; Hayat, M; Schultz, MJ | 1 |
| Feng, X; Jiang, Y; Liu, C; Qu, F; Xi, H; Zhao, X; Zhao, Y | 1 |
| Chen, CP; Cheng, CY; Cheng, SH; Lee, YL; Liao, CH; Lin, YC; Liu, CE | 1 |
| Ahsan, W; Alhazmi, HA; Bratty, MA; Javed, S; Najmi, A | 1 |
| Alwayn, IPJ; de Fijter, JW; de Vries, APJ; Janson, JA; Meziyerh, S; Moes, DJAR; Reinders, MEJ; van Etten, RW; van Gelder, T; Zwart, TC | 1 |
| Coumou, J; de Vries, PJ | 1 |
| Gadebusch Bondio, M; Marloth, M | 1 |
| Estella, Á; Garnacho-Montero, J | 1 |
| Marto, N; Monteiro, EC | 1 |
| Idid, SZ; Rahman, MT | 1 |
| Cheng, B; Li, T | 1 |
| Chen, K; Couban, RJ; Du, X; Gong, X; Guyatt, G; He, N; Ibrahim, QI; Li, X; Li, Y; Liu, F; Liu, J; Liu, W; Shen, N; Tang, Q; Wu, Z; Xu, X; Ye, Z; Ying, Y; Zhai, S; Zhang, Q; Zhang, Y; Zhou, P | 1 |
| Amore, A; Bimonte, S; Cascella, M; Celentano, E; Crispo, A; Cuomo, A | 1 |
| Chen, D; Dong, L; Pan, X; Peng, C; Yang, L | 1 |
| Cai, C; Deng, Y; Hu, ZY; Huang, K; Huang, Y; Wang, X; Wang, Y; Xie, J; Xie, Y; Xu, D; Zang, J; Zhan, T; Zheng, F | 1 |
| Chee, YJ; Tan, SK; Yeoh, E | 1 |
| Gafarova, AR; Gainullina, EN; Timerbulatov, SV; Timerbulatov, VM; Timerbulstov, MV | 1 |
| Chen, G; Chen, H; Chen, Y; Hong, Z; Huang, M; Liu, S; Liu, X; Shang, Y; Xia, J; Zhou, Y; Zhu, H | 1 |
| Chen, M; Chen, Z; Gao, G; Ma, X; Qian, F; Wang, A; Wang, S; Wang, X; Yu, F; Zhang, F; Zhang, J; Zhao, T | 1 |
| Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S | 1 |
| Filipova, E; Pavlova, V; Uzunova, K; Vekov, T | 1 |
| Chae, H; Jeong, HJ; Jeong, K; Kim, S; Lee, G; Min, S; Namgoong, SK | 1 |
| Guo, F; Li, S; Liu, C; Shang, D; Taleb, SJ; Tong, M | 1 |
| Alberici, I; Cattelan, AM; Di Meco, E; Farinati, F; Fassan, M; Guarnaccia, A; Trevenzoli, M | 1 |
| Antonijević Miljaković, E; Antonijević, B; Baralić, K; Buha Djordjevic, A; Ćurčić, M; Jorgovanović, D; Živančević, K; Đukić-Ćosić, D | 1 |
| Jones, CW; Platts-Mills, TF; Woodford, AL | 1 |
| Betancourt, JR; Domínguez, RE; González, D; López, LDR; Mezquia, N; Pereda, R; Pérez, A; Rivero, HB; Rivero, JC; Venegas, R | 1 |
| Alshaeri, HK; Natto, ZS | 1 |
| Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
| Ahuka-Mundeke, S; Bongo-Pasi Nswe, C; Hermans, MP; Ishoso, DK; Kayembe, JM; Kolié, MC; Machekano, RN; Madinga, JN; Mavungu Landu, DJ; Mbala-Kingebeni, P; Mbuyi, GM; Mellors, JW; Mills, EJ; Mofenson, L; Mukeba Tshialala, D; Mukendi, S; Muyembe-Tamfum, JJ; Nachega, JB; Nkwembe, EN; Nsio, JM; Otokoye, JO; Sam-Agudu, NA; Smith, G; Tshiasuma Pipo, M; Zumla, A | 1 |
| Baroutjian, A; Boneva, D; Elkbuli, A; McKenney, M; Sanchez, C | 1 |
| Chirachanakul, P; Punyaratabandhu, P | 1 |
| Campana, C; Dariolli, R; Gutierrez, A; Irurzun-Arana, I; Pullinger, TK; Sobie, EA; Varshneya, M | 1 |
| Mishra, SK; Tripathi, T | 1 |
| Albreem, MA; Alomari, OA; Alsharif, MH; Alsharif, YH; Hossain, MS; Jahid, A; Solyman, AAA; Yahya, K | 1 |
| Chen, X; Huang, Z; Kuang, Y; Liu, C; Liu, P; Pan, P; Yin, M | 1 |
| Ambrosino, I; Barbagelata, E; Ciarambino, T; Corbi, G; Moretti, AM; Politi, C | 1 |
| Govil, A; Luckett, K; Miller-Handley, H | 1 |
| Kumar, D; Trivedi, N; Verma, A | 1 |
| Betancourt, JR; Domínguez, RE; González, D; Lopez, LDR; Mezquia, N; Nodarse, H; Pereda, R; Pérez, A; Rivero, HB; Rivero, JC; Venegas, R | 1 |
| Dingding, Q; Jiangfang, L; Yujia, W; Zequn, Z | 1 |
| Asvadi-Kermani, T; Entezari-Maleki, T; Nouri-Vaskeh, M; Pourkarim, F; Pourtaghi-Anvarian, S; Rezaee, H | 1 |
| Wen, S; Xu, X; Yadav, AK; Yu, L | 1 |
| Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M | 1 |
| Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M | 1 |
| Danduga, RCSR; James, RA; Kandaswamy, DK; Raj, CTD; Rajasabapathy, R | 1 |
| Daouad, F; Haidar Ahmad, S; Herbein, G; Morot-Bizot, S; Nehme, Z; Pasquereau, S; Rohr, O; Schwartz, C; Van Assche, J; Wallet, C | 1 |
| Alotaibi, NH; Bokharee, N; Khan, YH; Khokhar, A; Mallhi, TH; Rasheed, M | 1 |
| Castillo-López, M; Farfán-Lazos, KC; Flores-Hernández, JR; Gómez-Núñez, MF; Hernández-Skewes, KY; Medina-Santos, D; Méndez-Coca, JD; Montaño-Olmos, D; Montiel-Bravo, G; Ortega-Rodríguez, S; Peón, AN; Román, PO; Romero-Lechuga, F; Roque-Reyes, OJ; Sevilla-Castillo, F; Tobón-Cubillos, M; Torres-Ortega, L; Viveros-Hernández, A | 1 |
| Brañez-Condorena, A; Diaz-Arocutipa, C; Hernandez, AV | 1 |
| Demiri, I; Dimkovski, A; Dimovski, A; Filipce, V; Grozdanova, A; Panovska-Stavridis, I; Ridova, N; Ristevska, T; Stevanovic, M; Stojanoska, T; Stojanovska, S | 1 |
| Angkasekwinai, N; Assanasen, S; Chayakulkeeree, M; Chierakul, N; Horthongkham, N; Jitmuang, A; Kantakamalakul, W; Koomanachai, P; Ratanarat, R; Rattanaumpawan, P; Rongrungruang, Y; Sirijatuphat, R; Suputtamongkol, Y; Wangchinda, W | 1 |
| Anedda, L; Bianchini, L; Cuzzolin, L; Fanos, V; Finco, G; Marcialis, MA | 1 |
| Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D | 1 |
| Bao, Y; Chen, Z; Ding, J; Feng, Y; Guan, H; Li, H; Liu, W; Wang, X; Zhou, Z | 1 |
| Cai, T; Fu, L; Hu, Y; Huang, Z; Xiong, Z; Ye, H; Zhang, S; Zheng, N; Zhu, H | 1 |
| Abayomi, A; Abdur-Razzaq, H; Anya, SE; Erinoso, OA; Ezechi, O; Kuyinu, Y; Ojo, O; Ola, B; Osibogun, A; Wright, K; Zamba, E | 1 |
| Bhardwaj, M; Chiu, MN; Sah, SP | 1 |
| Akbal-Dagistan, O; Basarir, NS; Culha, M; Erturk, A; Sahin, G; Sancar, S; Yildiz-Pekoz, A | 1 |
| Alsmadi, MM | 1 |
| Chen, M; Dai, W; Yang, F; Yang, K; Zeng, J | 1 |
36 review(s) available for chloroquine and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Immunomodulation; Interferon-alpha; Lopinavir; Nelfinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Purines; Pyrazoles; Ribavirin; Ritonavir; SARS-CoV-2; Sulfonamides; Thiazoles | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
Antiviral treatment of COVID-19
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Nitro Compounds; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2; Thiazoles | 2020 |
Respiratory Support in COVID-19 Patients, with a Focus on Resource-Limited Settings.
Topics: Adenosine Monophosphate; Alanine; Betacoronavirus; Chloroquine; Continuous Positive Airway Pressure; Coronavirus Infections; COVID-19; Developing Countries; Disease Management; Humans; Hydroxychloroquine; Lopinavir; Lung; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Basal Metabolism; Betacoronavirus; Cardiovascular Physiological Phenomena; Chloroquine; Congenital Abnormalities; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Susceptibility; Drug Combinations; Drug Delivery Systems; Female; Functional Residual Capacity; Glycyrrhizic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Interferon Type I; Lopinavir; Metformin; Nanoparticles; Oxygen Consumption; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prognosis; Respiratory Physiological Phenomena; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Stillbirth; Ventilation-Perfusion Ratio | 2020 |
Treatment of SARS-CoV-2: How far have we reached?
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Darunavir; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferon-alpha; Interferon-beta; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
Medicines for the Treatment Of COVID-19: Awaiting the Evidence.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Investigational; Global Health; Humans; Hydroxychloroquine; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Can Zn Be a Critical Element in COVID-19 Treatment?
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Humans; Lopinavir; Ritonavir; Zinc | 2021 |
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Evidence-Based Medicine; Humans; Hydroxychloroquine; Indoles; Influenza, Human; Lopinavir; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Interferons; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Survival Analysis | 2020 |
Dissecting the interaction between COVID-19 and diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucagon-Like Peptide-1 Receptor; Glycemic Control; Humans; Hydroxychloroquine; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Interferon Type I; Lopinavir; Lung; Metformin; Obesity; Pancreas; Ritonavir; Severity of Illness Index; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2020 |
[Drug treatment of coronavirus disease COVID-19: evidence exists?]
Topics: Adenosine Monophosphate; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tissue Plasminogen Activator | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arrhythmias, Cardiac; Chloroquine; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Electrocardiography; Heart Failure; Humans; Hydroxychloroquine; Hypoxia; Inflammation; Long QT Syndrome; Lopinavir; Myocarditis; Myocardium; Precipitating Factors; Receptors, Interleukin-6; Respiratory Distress Syndrome; Ribavirin; Ritonavir; SARS-CoV-2; Water-Electrolyte Imbalance | 2021 |
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Combinations; Drugs, Chinese Herbal; Humans; Indoles; Janus Kinase Inhibitors; Lopinavir; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A contemporary look at COVID-19 medications: available and potentially effective drugs.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Imatinib Mesylate; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2 pharmacologic therapies and their safety/effectiveness according to level of evidence.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Drug Combinations; Evidence-Based Medicine; Humans; Hydroxychloroquine; Interferon beta-1b; Lopinavir; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Systematic Reviews as Topic | 2020 |
One year update on the COVID-19 pandemic: Where are we now?
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses | 2021 |
Application of machine intelligence technology in the detection of vaccines and medicines for SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Artificial Intelligence; Ascorbic Acid; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Deep Learning; Drug Combinations; Drug Development; Drug Repositioning; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Machine Learning; Ribavirin; Ritonavir; Vitamins | 2020 |
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Creatinine; Cytidine; Dexamethasone; Drug Combinations; Drug Interactions; Humans; Hydroxychloroquine; Hydroxylamines; Immunization, Passive; Interferons; Janus Kinase Inhibitors; Lopinavir; Pyrazines; Renal Elimination; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ribavirin; Ritonavir; SARS-CoV-2 | 2020 |
Possible treatment and strategies for COVID-19: review and assessment.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; Cannabinoids; Chloroquine; Complement Inactivating Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; COVID-19 Vaccines; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles | 2020 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Channel; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Ritonavir | 2021 |
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Drug Interactions; Humans; Lopinavir; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Topics: Adenosine Monophosphate; Alanine; Amides; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azetidines; Chloroquine; COVID-19; COVID-19 Serotherapy; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Nitro Compounds; Oseltamivir; Purines; Pyrazines; Pyrazoles; Ribavirin; Ritonavir; Sulfonamides; Thiazoles | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Databases, Factual; Humans; Hydroxychloroquine; Immunoglobulins; Lopinavir; Pandemics; Pyrazines; Respiration, Artificial; Ritonavir; SARS-CoV-2 | 2021 |
COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Serotherapy; Dexamethasone; Drug Repositioning; Evolution, Molecular; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Phylogeny; Prospective Studies; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2 | 2021 |
Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Intensive Care Units; Length of Stay; Lopinavir; Methylprednisolone; Observational Studies as Topic; Patient Admission; Pyrazines; Ritonavir; SARS-CoV-2; Survival Rate | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Observational Studies as Topic; Ritonavir | 2021 |
Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Dexamethasone; Drug Combinations; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunologic Factors; Lopinavir; Ritonavir; SARS-CoV-2 | 2021 |
What if COVID-19 affects the child: which weapons and how to use them.
Topics: Adenosine Monophosphate; Adolescent; Age Factors; Alanine; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Carrier State; Child; Child, Preschool; Chloroquine; Continuous Renal Replacement Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Extracorporeal Membrane Oxygenation; Glucocorticoids; Humans; Hydroxychloroquine; Immunization, Passive; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Oseltamivir; Receptors, Cell Surface; Respiration, Artificial; Ribavirin; Ritonavir; SARS-CoV-2; Severity of Illness Index; Thrombosis | 2021 |
Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Topics: Adenosine Monophosphate; Alanine; Amides; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inducers; Dexamethasone; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Epilepsy; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2 | 2021 |
Safety profile of COVID-19 drugs in a real clinical setting.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Ivermectin; Lopinavir; Reproducibility of Results; Ritonavir; SARS-CoV-2 | 2022 |
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
Topics: Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Heparin; Humans; Hydroxychloroquine; Lopinavir; Ritonavir; SARS-CoV-2 | 2022 |
A systematic review and Bayesian network meta-analysis for comparative safety assessment of favipiravir interventions in hospitalized COVID-19 patients.
Topics: Amides; Chloroquine; COVID-19 Drug Treatment; Humans; Lopinavir; Network Meta-Analysis; Pyrazines; Ritonavir; SARS-CoV-2; Treatment Outcome | 2022 |
4 trial(s) available for chloroquine and ritonavir
| Article | Year |
|---|---|
Treating COVID-19 with Chloroquine.
Topics: Adult; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Humans; Lopinavir; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Case-Control Studies; China; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Indoles; Interleukin-17; Lopinavir; Middle Aged; Ribavirin; Ritonavir; Safety; SARS-CoV-2; Th17 Cells; Treatment Outcome | 2020 |
A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomi
Topics: Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Lopinavir; Multicenter Studies as Topic; Nigeria; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2021 |
50 other study(ies) available for chloroquine and ritonavir
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro.
Topics: Animals; Antimalarials; Chloroquine; Drug Synergism; HIV Protease Inhibitors; Humans; Malaria, Falciparum; Mefloquine; Parasitic Sensitivity Tests; Plasmodium falciparum; Ritonavir; Saquinavir | 2007 |
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.
Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir | 2008 |
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
Topics: Animals; Antimalarials; Drug Resistance, Multiple; Gene Dosage; Genes, MDR; Genes, Protozoan; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Malaria, Falciparum; Malaria, Vivax; Parasitic Sensitivity Tests; Plasmodium falciparum; Plasmodium vivax; Ritonavir; Saquinavir | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.
Topics: Animals; Antimalarials; Darunavir; Erythrocytes; HIV Protease Inhibitors; Humans; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyridines; Pyrones; Sulfonamides | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Evaluation of aminohydantoins as a novel class of antimalarial agents.
Topics: | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Synthesis and biological evaluation of bis-N
Topics: Antifungal Agents; Antitubercular Agents; Catalytic Domain; Coumarins; HeLa Cells; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Protein Binding; Trypanocidal Agents; Trypanosoma brucei brucei | 2020 |
Antimalarial activity of sera from subjects taking HIV protease inhibitors.
Topics: Animals; Antimalarials; Antiretroviral Therapy, Highly Active; Chloroquine; Drug Synergism; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria, Falciparum; Plasmodium falciparum; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome | 2007 |
Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.
Topics: Animals; Anti-Retroviral Agents; Antimalarials; Chloroquine; Drug Resistance; Drug Synergism; Female; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; HIV Protease Inhibitors; Inhibitory Concentration 50; Malaria; Mice; Nelfinavir; Plasmodium chabaudi; Plasmodium falciparum; Ritonavir; Saquinavir | 2009 |
Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.
Topics: Animals; Antimalarials; Biological Transport; Chloroquine; Drug Combinations; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Lopinavir; Malaria, Falciparum; Membrane Transport Proteins; Mutation; Oocytes; Plasmodium falciparum; Protozoan Proteins; Ritonavir; Saquinavir; Tritium; Xenopus laevis | 2012 |
More than 80 clinical trials launch to test coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Dioxanes; Disease Models, Animal; Drug Combinations; Humans; Immunization, Passive; Lopinavir; Medicine, Chinese Traditional; Monosaccharides; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Stem Cell Transplantation; Steroids; Time Factors; Treatment Outcome; World Health Organization | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Race to find COVID-19 treatments accelerates.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Biomedical Research; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
Combating COVID-19 with Chloroquine.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Endocytosis; Humans; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Neuraminidase; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ribavirin; Ritonavir; SARS-CoV-2; Taiwan; Virus Shedding | 2020 |
Severe COVID-19 in a renal transplant recipient: A focus on pharmacokinetics.
Topics: Adult; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drug Interactions; Everolimus; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Netherlands; Pandemics; Pneumonia, Viral; Radiography, Thoracic; Ritonavir; SARS-CoV-2; Transplant Recipients; Treatment Outcome | 2020 |
[Chloroquine as a possible treatment for COVID-19].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Humans; Lopinavir; Off-Label Use; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome | 2020 |
[The "Historic Study" SOLIDARITY-Research's Answer to the Sars-CoV-2 Pandemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Bioethical Issues; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Combinations; Editorial Policies; Humans; Hydroxychloroquine; International Cooperation; Lopinavir; Pandemics; Pneumonia, Viral; Research Design; Ritonavir; SARS-CoV-2; World Health Organization | 2020 |
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Decision-Making; Clinical Trials as Topic; Coronavirus Infections; Cost-Benefit Analysis; COVID-19; Drug Combinations; Empiricism; Humans; Hydroxychloroquine; Information Dissemination; Lopinavir; Pandemics; Pneumonia, Viral; Reproducibility of Results; Ritonavir; SARS-CoV-2; Viral Load | 2020 |
Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.
Topics: Adenosine Monophosphate; Alanine; Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus 3C Proteases; Cysteine; Cysteine Endopeptidases; Molecular Docking Simulation; Ritonavir; SARS-CoV-2; Viral Nonstructural Proteins | 2020 |
Treatment strategies of hospitalized patients with coronavirus disease-19.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; China; Chloroquine; Coronavirus Infections; COVID-19; Drug Combinations; Drugs, Chinese Herbal; Female; gamma-Globulins; Glucocorticoids; Hospitalization; Humans; Immunologic Factors; Indoles; Interferons; Lopinavir; Male; Middle Aged; Oxygen; Pandemics; Pneumonia, Viral; Respiration, Artificial; Retrospective Studies; Ritonavir; SARS-CoV-2 | 2020 |
Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients.
Topics: Adult; Antimalarials; Chloroquine; Chronic Disease; Coronavirus Infections; COVID-19; Drug Combinations; Female; Fever; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2020 |
Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
Topics: Amides; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Discovery; Humans; Lopinavir; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pandemics; Pneumonia, Viral; Pyrazines; Ritonavir; SARS-CoV-2 | 2020 |
SARS-CoV-2 and hepatitis.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Betacoronavirus; Chemical and Drug Induced Liver Injury; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Diagnosis, Differential; Drug Combinations; Hepatitis, Viral, Human; Humans; Liver; Liver Function Tests; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Databases, Genetic; Drug Therapy, Combination; Gene Regulatory Networks; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Toxicogenetics | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Double-Blind Method; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Single-Blind Method; Stem Cell Transplantation | 2020 |
Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Chloroquine; Coronavirus Infections; COVID-19; Cuba; Drug Therapy, Combination; Female; Humans; Infant; Interferon alpha-2; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prospective Studies; Ritonavir; SARS-CoV-2; Young Adult | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Democratic Republic of the Congo; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Hospitals; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Obesity; Pandemics; Patient Discharge; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2020 |
Cutaneous eruption in COVID-19-infected patients in Thailand: An observational descriptive study.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Eruptions; Exanthema; Female; Humans; Lopinavir; Male; Middle Aged; Ritonavir; SARS-CoV-2; Young Adult | 2021 |
Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.
Topics: Action Potentials; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Models, Theoretical; Myocytes, Cardiac; Risk Factors; Ritonavir; Therapies, Investigational | 2021 |
Gender differences in treatment of Coronavirus Disease-2019.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Amides; Antimalarials; Antiviral Agents; Cardiovascular Diseases; Chloroquine; Clinical Trials as Topic; Combined Modality Therapy; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Complications; Female; Humans; Hypertension; Immunity; Immunization, Passive; Immunoglobulins; Lopinavir; Male; Middle Aged; Mortality; Pandemics; Pyrazines; Ritonavir; SARS-CoV-2; Sex Characteristics | 2020 |
Therapeutic Effectiveness of Interferon Alpha 2b Treatment for COVID-19 Patient Recovery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Chloroquine; Comorbidity; COVID-19; Critical Care; Cuba; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Interferon alpha-2; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome; Young Adult | 2020 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines | 2021 |
Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.
Topics: Antiviral Agents; Cell Line; Chloroquine; Coronavirus 229E, Human; Drug Repositioning; Humans; Lopinavir; Male; Resveratrol; Ritonavir; SARS-CoV-2; Viral Load; Virus Replication | 2021 |
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index; Young Adult | 2021 |
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand's university-based referral hospital.
Topics: Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Darunavir; Disease Progression; Drug Combinations; Female; Hospitals; Hospitals, University; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Pyrazines; Referral and Consultation; Retrospective Studies; Ritonavir; Thailand; Treatment Outcome; Young Adult | 2021 |
Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Topics: Aged; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Drugs, Chinese Herbal; Electrocardiography; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Indoles; Interferons; Long QT Syndrome; Lopinavir; Male; Middle Aged; Odds Ratio; Quinolones; Retrospective Studies; Ritonavir; SARS-CoV-2; Severity of Illness Index | 2021 |
Risk factors for prolonged virus shedding of respiratory tract and fecal in adults with severe acute respiratory syndrome coronavirus-2 infection.
Topics: Adult; Animals; Antiviral Agents; CD4 Lymphocyte Count; Chloroquine; COVID-19; Feces; Female; Humans; Killer Cells, Natural; Longitudinal Studies; Lopinavir; Lynx; Male; Obesity; Respiratory System; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Time Factors; Virus Shedding | 2021 |
The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling.
Topics: Adult; Chloroquine; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Ivermectin; Lopinavir; Ritonavir | 2023 |